Non-infectious complications of transfusion therapy

Blood Reviews

Volumn 15, Issue 2, 2001, Pages 69-83

  Perrotta, P L ^a   Snyder, E L ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALLERGIC REACTION; BLOOD ANALYSIS; BLOOD TRANSFUSION; EXTRACELLULAR SPACE; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC DISORDER; PRIORITY JOURNAL; PURPURA; REVIEW; SAFETY; SCREENING TEST; SEPSIS; URTICARIA;

EID: 0034934972     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0151     Document Type: Article

References (159)

1. Current viral risks of blood and blood products
2. HIV, HBV and HCV: New developments related to transfusion safety
3. Transmission of parasites and bacteria by blood components
4. Serious hazards of transfusion (SHOT) initiative: Analysis of the first two annual reports
5. Immunological aspects of blood transfusions
6. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: New insights into pathophysiology and treatment
7. Delayed hemolytic transfusion reactions. An often-missed entity
8. Delayed hemolytic transfusion reactions. Evidence of the need for an improved pretransfusion compatibility test
9. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions
10. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells
11. Delayed hemolytic transfusion reaction caused by a primary immune response
12. The role of cytokines in hemolytic transfusion reactions
13. Release of mediators of systemic inflammatory response syndrome in the course of a severe delayed hemolytic transfusion reaction caused by anti-D
14. Transfusion reaction. An immunologic hazard of blood transfusion
15. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: Incidence and predictors of hemolysis
16. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: Incidence, long-term serologic findings, and clinical significance
17. When should antibody screening tests be done for recently transfused patients?
18. Case reports: Delayed hemolytic transfusion reaction in sickle cell disease
19. The sickle cell hemolytic transfusion reaction syndrome
20. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: Use of steroids and intravenous immunoglobulin to prevent further red cell destruction
21. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions
22. Meperidine (pethidine) to control shaking chills and fever associated with non-hemolytic transfusion reactions
23. Biological response modifiers in platelet transfusion therapy
24. Febrile reactions after platelet transfusion: The effect of single versus multiple donors
25. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats
26. The role of the plasma from platelet concentrates in transfusion reactions
27. The relationship between the duration of platelet storage and the development of transfusion reactions
28. Demonstration by flow cytometry of the numbers of residual white blood cells and platelets in filtered red blood cell concentrates and plasma preparations
29. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
30. Leukocyte reduction ultraviolet B irradiation of platelets to prevent alloimmunization refractoriness to platelet transfusions
31. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage
32. Cytokine generation in stored platelet concentrates
33. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations
34. Adverse reactions associated with autologous blood transfusion: Evaluation and incidence at a large academic hospital
35. Impact of allergy screening for blood donors: Relationship to nonhemolytic transfusion reactions
36. Is allergy screening of blood donors necessary? A comparison between questionnaire answers and the presence of circulating IgE antibodies
37. Presence of aspirin in blood units
38. The utility of platelet washing using an automated procedure for severe platelet allergic reactions
39. Transfusion management of patients with IgA deficiency and anti-IgA during liver transplantation
40. Ethylene oxide and anaphylaxis during haemodialysis
41. Compatibility of common intravenous solutions with CPD blood
42. Extracorporeal hemolysis of blood in a microwave blood warmer
43. Hemolytic and pseudo-hemolytic transfusion reactions: An overview of the hemolytic transfusion reactions and the clinical conditions that mimic them
44. Needles and hemolysis
45. Hemoglobinemia and hemoglobinuria complicating concomitant use of a white cell filter and a pressure infusion device
46. Reducing the risk of bacterial contamination of cellular blood components
47. Glucose-6-phosphate dehydrogenase deficiency
48. A method for freezing and washing red blood cells using a high glycerol concentration
49. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: New insights into pathophysiology and treatment
50. Post-transfusion purpura
51. Post-transfusion purpura
52. Post-transfusion purpura: A survey of 12 Danish cases with special reference to immunoglobulin G subclasses of the platelet antibodies
53. Post-transfusion thrombocytopenic purpura: Immunological and clinical studies in two cases and review of the literature
54. Post-transfusion purpura: A serological and immunochemical study
55. Post-transfusion purpura associated with anti-Baka and anti-PIA2 platelet antibodies and delayed haemolytic transfusion reaction
56. Post-transfusion purpura: Clinical and immunologic studies in 38 patients
57. Post-transfusion purpura: A heterogeneous syndrome
58. Post-transfusion purpura and multiple transfusions
59. Pan-reactive platelet antibodies in post-transfusion purpura
60. High-dose IgG for post-transfusion purpura-revisited
61. High-dose intravenous immunoglobulin for post-transfusion purpura
62. Effect of intravenous immunoglobulin in immune thrombocytopenia
63. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
64. Post-transfusion purpura: Successful treatment by exchange transfusion
65. Apparent response of refractory post-transfusion purpura to splenectomy
66. Post-transfusion purpura: A report of five patients and a review of the pathogenesis and management
67. Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin
68. Post-transfusion purpura due to HPA-la immunization in a male patient: Response to subsequent multiple HPA-la-incompatible red-cell transfusions
69. The therapeutic value of HPA-la-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage
70. Posttransfusion purpura: The therapeutic value of PIAI-negative platelets
71. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
72. Complications of therapeutic plasma exchange: A recent assessment
73. Transfusion haemosiderosis and chelation therapy
74. Transfusional iron overload
75. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation
76. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy
77. Diabetic nephropathy in hypertransfused patients with beta-thalassemia. The role of oxidative stress
78. Effect of transfusional iron overload on immune response
79. Continuous subcutaneous administration of deferoxamine in patients with iron overload
80. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
81. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study
82. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (LI): A Dutch multicenter trial
83. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
84. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
85. Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies
86. Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin 5 level and reducing iron overload
87. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients
88. Quantification of liver iron overload by T2 quantitative magnetic resonance imaging in thalassemia: Impact of chronic hepatitis C on measurements
89. Iron overloadin reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations
90. Massive transfusion and hyperkalaemic cardiac arrest in craniofacial surgery in a child
91. Comparison of Adsol and CPDA-I blood preservatives during simulated massive resuscitation after hemorrhage in swine
92. Altered contractile response in neonatal myocardium to citrate-phosphate-dextrose infusion
93. Effects of citrated whole blood transfusion in response to hemorrhage
94. Severe hypercalcemia following neonatal liver transplantation
95. Factors influencing the ionization of calcium during major surgical procedures
96. Blood exchange transfusions in newborns, the effect on serum ionized calcium
97. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans
98. Ionized calcium levels during liver transplantation
99. Compatibility of blood with solutions containing calcium
100. Serum ionized magnesium monitoring during orthotopic liver transplantation
101. How to stabilize the level of ionized calcium and citrate during plateletpheresis
102. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood
103. Concentration of citrate anticoagulant in peripheral blood progenitor cell collections
104. Fatal air embolism due to perioperative blood recovery
105. Blood substitutes Artificial oxygen carriers: Perfluorocarbon emulsions
106. Mild perioperative hypothermia
107. Blood warming: Current applications and techniques
108. Perioperative thermoregulation and heat balance
109. Hypotensive reactions: A previously uncharacterized complication of platelet transfusion?
110. Hypotensive reactions associated with platelet transfusions and angiotensin-converting enzyme inhibitors
111. Quality of platelet components: The role of suspension medium and leukocyte depletion
112. Hypotensive reactions with a white cell-reduction filter: Activation of kallikrein-kinin cascade in a patient
113. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter
114. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets
115. Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE Inhibitors
116. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensiv reactions during blood transfusions: A preliminary study
117. Adverse ocular reactions following transfusions - United States 1997-1998
118. Adverse periocular reaction after blood transfusion
119. Post transfusion septicaemia 1980-1989: Importance of donor arm cleansing
120. The Serious Hazards of Transfusion (SHOT) initiative: The UK approach to haemovigilance
121. Transfusion-transmitted bacterial infection
122. Red blood cell transfusions contaminated with Yersinia enterocolitica - United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions
123. Fatal Salmonella septicemia after platelet transfusion
124. Bacteriological and serological findings in a further case of transfusion-mediated Yersinia enterocolitica sepsis
125. Transfusion-related sepsis due to Serratia liquefaciens in the United States
126. Septic shock due to Yersinia enterocolitica after autologous transfusion
127. Transfusion-related sepsis after prolonged platelet storage
128. Bacterial contamination of blood components
129. Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or -80 degrees C
130. Rapid identification of bacterially contaminated platelets using reagent strips: Glucose and pH analysis as markers of bacterial metabolism
131. Reduction of platelet transfusion-associated sepsis by short-term bacterial culture
132. Photochemical inactivation of pathogenic bacteria in human platelet concentrates
133. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
134. The use of riboflavin for the inactivation of pathogens in blood products
135. A prospective study of symptomatic bacteremia following platelet transfusion and of its management
136. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery
137. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients
138. Graft-versus-host disease: New directions for a persistent problem
139. Transfusion-associated graft-versus-host disease: An in situ hybridization analysis of the infiltrating donor-derived cells in the cutaneous lesion
140. Treatment of transfusion-associated graft-versus-host disease
141. Transfusion-associated graft-versus-host disease in immunocompetent patient: Early diagnosis and therapy
142. Therapeutic strategy for post-transfusion graft-vs.-host disease
143. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxicT-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones
144. Transfusion-associated graft-versus-host disease and its prevention
145. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA Class I antigens
146. Dosimetry of blood irradiation with radiochromic film
147. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters
148. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment
149. Pulomonary edema in the course of a blood transfusion without overloading the circulation
150. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury
151. Transfusion-related acute lung injury: A neglected, serious complication of hemotherapy
152. Transfusion-related acute lung injury
153. Reproduction of transfusion-related acute lung injury in an ex vivo lung model
154. The pathology of transfusion-related acute lung injury
155. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model
156. Transfusion-related acute lung injury following random donor platelet transfusion: A report of two cases
157. Prevalence of HLA sensitization in female apheresis donors
158. Reports of 355 transfusion-associated deaths: 1976 through 1985